This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
As we all grapple with what this means at this preliminary stage and then what could evolve over time, I focus on the dual aspect of the opportunity: is this about primarycare or is this about data? ” I added the bold emphasis here on the issue of personal healthdata. To be sure, it’s both.
This growth is expected to create opportunities for M&A activity, as pharmaceutical companies look to acquire smaller, innovative biotech companies. This trend is expected to continue in 2023, particularly in the areas of primarycare, diagnostics, and hospital services.
To address that challenge, in 2017 PLM secured a $100 million (controlling interest) investment from iCarbonX , a Chinese company that is amassing patient data to discover cures for disease. When this occurred, it didn’t cause more than a ripple of interest outside biotech. citizens’ personal data. But the U.S.
Movano Health:A women's health company that develops and sells smart jewelry that tracks healthdata. IPO date of March 22, 2021 Movano Health in the last 2 years has focused on developing and gaining regulatory approval for the Evie Ring, a women's health smart ring.
Movano Health: A women's health company that develops and sells smart jewelry that tracks healthdata. IPO date of March 22, 2021 Movano Health in the last 2 years has focused on developing and gaining regulatory approval for the Evie Ring, a women's health smart ring.
We organize all of the trending information in your field so you don't have to. Join 48,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content